Aspen Aerogels to Present at the 37th Annual ROTH Conference
Donald R. Young, President & CEO, will be hosting one-on-one and small group meetings with investors during the conference.
In addition, the conference will feature a Fireside Chat with Mr. Young, hosted by ROTH Capital's Managing Director and Senior Research Analyst, Chip Moore. The Fireside Chat is scheduled for 10:30 a.m. - 10:55 a.m. PT. A live webcast of the Fireside Chat can be accessed on the Investor Relations section of Aspen's website and will be available for one year.
For those interested in arranging a one-on-one or small group meeting with Aspen management, please contact your ROTH Capital representative.
About Aspen Aerogels, Inc.Aspen is a technology leader in sustainability and electrification solutions. The Company's aerogel technology enables its customers and partners to achieve their own objectives around the global megatrends of resource efficiency, e-mobility and clean energy. Aspen's PyroThin® products enable solutions to thermal runaway challenges within the electric vehicle ("EV") market. The Company's carbon aerogel initiative seeks to increase the performance of lithium-ion battery cells to enable EV manufacturers to reduce charging time and the cost of EVs. The Company's Cryogel® and Pyrogel® products are valued by the world's largest energy infrastructure companies. Aspen's strategy is to partner with world-class industry leaders to leverage its Aerogel Technology Platform® into additional high-value markets. Aspen is headquartered in Northborough, Mass. For more information, please visit www.aerogel.com.
View original content:https://www.prnewswire.com/news-releases/aspen-aerogels-to-present-at-the-37th-annual-roth-conference-302392169.html
SOURCE Aspen Aerogels, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
AI could deliver $920B in annual net benefits to S&P 500 firms
-- Artificial intelligence could generate annual net benefits of roughly $920 billion for S&P 500 companies, according to Morgan Stanley (NYSE:MS). The bank said in a note Monday that its analysis points to '$13-16 trillion in long-term market value creation potential for the S&P 500' driven by AI adoption. The report highlights that '90% of occupations will to some degree be impacted by AI automation and augmentation,' with the potential benefits coming from both cost reductions and productivity gains. Morgan Stanley noted that agentic AI, essentially software-based applications, will likely have 'a broader impact on jobs relative to embodied AI,' with greater scope for augmentation rather than outright replacement. Sector exposure is said to vary widely. The bank found that Consumer Staples Distribution/Retail, Real Estate Management & Development, and Transportation could each see savings above 100% of estimated 2026 pretax earnings. Health Care Equipment & Services was also flagged as a major beneficiary. By contrast, Technology Hardware & Equipment and Semiconductors show relatively muted effects. Morgan Stanley emphasised that the value creation potential, equal to 24-29% of current S&P 500 market capitalisation, is 'fundamentally bullish for AI enablers and adopters.' It added that the return on the roughly $3 trillion in expected global AI capex through 2028 in areas such as data centres and chips 'is attractive.' While the $920 billion figure represents a full-adoption scenario that may take years to achieve, the bank argued that the long-term opportunity is likely far larger. 'AI adoption market value creation potential, beyond the confines of the S&P 500, is likely to be multiples of the $13-16 trillion,' Morgan Stanley said. Related articles AI could deliver $920B in annual net benefits to S&P 500 firms Madrigal stock falls after Novo Nordisk's Wegovy wins FDA approval for MASH Evercore ISI initiates tactical calls on BJ's, Target and Lowe's ahead of earnings
Yahoo
5 minutes ago
- Yahoo
Should You Consider Adding Taseko Mines (TGB) to Your Portfolio?
Diamond Hill Capital, an investment management company, released its 'Small-Mid Cap Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q2, the market surged uniformly for the rest of the quarter following a sharp decline in April due to President Trump's 'Liberation Day' tariffs announcement. The portfolio returned 5.60% (gross) and 5.37% (net) compared to an 8.59% return for the Russell 2500 Index. For more information on the fund's top picks in 2025, please check its top five holdings. In its second-quarter 2025 investor letter, Diamond Hill Small-Mid Cap Fund highlighted stocks such as Taseko Mines Limited (NYSE:TGB). Taseko Mines Limited (NYSE:TGB) is a mining company that operates mineral properties. The one-month return of Taseko Mines Limited (NYSE:TGB) was 0.93%, and its shares gained 43.42% of their value over the last 52 weeks. On August 15, 2025, Taseko Mines Limited (NYSE:TGB) stock closed at $3.27 per share, with a market capitalization of $1.039 billion. Diamond Hill Small-Mid Cap Fund stated the following regarding Taseko Mines Limited (NYSE:TGB) in its second quarter 2025 investor letter: "Despite markets' relatively sharp bounce following April's downward volatility, we were able to initiate several new positions in the quarter at what we consider compelling valuations: Generac Holdings, Alaska Air Group, Knife River Corporation, Taseko Mines Limited (NYSE:TGB), Century Communities and FTI Consulting. Aerial view of the Yellowhead copper project, the scale of the landscape revealed. Taseko Mines Limited (NYSE:TGB) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held Taseko Mines Limited (NYSE:TGB) at the end of the first quarter, which was 12 in the previous quarter. While we acknowledge the potential of Taseko Mines Limited (NYSE:TGB) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Taseko Mines Limited (NYSE:TGB) and shared the list of best gold penny stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
5 minutes ago
- Yahoo
UBS upgrades CVS, says turnaround in health benefits business gaining traction
-- UBS upgraded CVS Health (NYSE:CVS) to Buy from Neutral and raised its price target to $79, saying recent cost controls and execution in the company's healthcare benefits arm are beginning to show results and the improvement is not yet priced into the stock. The brokerage said CVS has posted two consecutive quarters of stronger-than-expected results, helped by better forecasting of Medicare Advantage utilization and early signs that fixes to its underperforming group insurance segment are working. UBS now expects CVS earnings to grow at a 14% compound annual rate through 2028, above its previous forecast and the Street's estimated 12%. Analysts pointed to CVS correctly cutting benefits and recalibrating assumptions in its Medicare Advantage plans for this year, leading to a more stable claims trend and meaningful reserve release. They estimate the group Medicare Advantage business, where roughly half of contracts are being repriced in 2025, could move from negative mid-to-high single-digit margins to positive territory, contributing an estimated $0.46 per share in 2026 earnings. UBS also expects CVS to return to roughly 3.5x leverage by late 2026, creating room for share buybacks and further earnings growth. At around nine times 2026 earnings, the stock trades below its long-term historical average of 10 times, despite a reaccelerating growth profile. Risks include potential deterioration in Medicare Star quality ratings in October, and pending U.S. regulation on drug pricing or pharmacy-benefit managers. But UBS said CVS remains confident in its Stars positioning, noting that about 65% of plan members are in contracts rated 4.5 stars or higher well above the bonus threshold. Related articles UBS upgrades CVS, says turnaround in health benefits business gaining traction Bernstein upgrades Toyota stock as journey to 20% RoE kicks off AI could deliver $920B in annual net benefits to S&P 500 firms Sign in to access your portfolio
